

Index

Numbers in italics indicate *tables* or *figures*, *cp* denotes colour plate.

- N-acetyl aspartate (NAA)
 - levels in cerebral ischemia 237, 238, 242, *cp*
 - levels in normal brain 237, 240–1
 - in outcome prediction 185, 245
 - reversible changes 244, 245
- age and stroke therapy 9
- ancrod 113
- aneurysms, detection of 95–6
- animal stroke models
 - DWI studies 114, *cp*
 - neuroprotective therapy 116–17, *cp*
 - reperfusion injury 114–15
- DWI–PWI combined studies
 - diffusion–perfusion mismatch 115
 - mechanical reperfusion 117
 - neuroprotective therapy 118
 - thrombolytic therapy 117–18
- PWI studies 115, 117, 168
- use in preclinical evaluation of therapies 113–14, 116
- aortic embolisms 6
- apparent diffusion coefficient (ADC)
 - anisotropic 59
 - effects of ischemia on 114, 198–9
 - effects of reperfusion on 114–15, 210
 - maps 57, 60, 122
 - trace ADC 61
- arterial hemorrhagic infarcts 79
- arterial obstruction, detection by CT 32, 36
- arterial spin labelling (ASL) 62–3, 148, 161–74
 - clinical applications in stroke 168–71
 - labelling strategies
 - continuous 162–3, 163–4
 - pulsed 163
 - to overcome transit delays 171–2
 - motion artefact reduction 164–6
 - multislice imaging 166–7
 - perfusion mapping in animal models 168
 - principle 161–2
 - quantification of perfusion 164
 - subtraction method 162, 163
 - validation 168
- aspirin 1
- blood
 - appearance in MR images 85
 - see also* cerebral blood flow (CBF)
 - evaluation; cerebral blood volume (CBV) evaluation
 - blood oxygen level dependent (BOLD)
 - imaging 202, 251–2
 - blood pressure
 - management in intracerebral hemorrhage 50–1
 - and stroke risk 8
 - blood–brain barrier 148
 - brain imaging in stroke
 - goals 208
 - importance 15
 - modalities compared 176
 - patient factors 15
 - see also specific imaging modalities*
 - brain tissue swelling, detection by CT 32–5, 36
 - brain tumors, differentiation from infarcts 79, 81
 - cardiac-origin embolism 6, 182
 - carotid artery, imaging by MRA 89–93, 94
 - carotid endarterectomy 7, 89
 - CE 3DMRA *see* contrast-enhanced MRA (CE-MRA)
 - cerebral blood flow (CBF) evaluation
 - acute stroke 48–9
 - chronic cerebral ischemia 49–50
 - CT-based 47–54
 - intracerebral hemorrhage 50–1
 - PET-based 24
 - PWI-based 62, 63, 152–4
 - subarachnoid hemorrhage 51
 - vasospasm 51
 - cerebral blood volume (CBV) evaluation
 - PET-based 24–5
 - PWI-based 62, 150–2
 - cerebral glucose metabolism, measurement by PET 25
 - cerebral oxygen metabolism, measurement by PET 25
 - cerebral perfusion pressure (CPP) 154–5
 - cerebral venous thrombosis 4
 - cerebritis, differentiation from infarcts 81, 83
 - cerebrovascular reserve, characterization with ASL 169, 170, 171
 - Cerestat 116
 - Ceretec 22
 - cervical vascular lesions 7
 - chemical shift imaging (CSI) 185–6, 233, 234
 - choline measurement by MRS
 - cerebral ischemia 237, 242
 - normal brain 237, 241
 - circle of Willis, evaluation by MRA 93–7
 - citicoline trials 183, 227
 - computed tomographic angiography (CTA) 18–19, 52, 90–1, 94, 95
 - computed tomographic perfusion imaging (CTP) 19, 51–2, 196, 197
 - computed tomography (CT)
 - CBF evaluation 47–54
 - in pregnancy 16
 - principle 16
 - radiation exposure 16
 - sequence of changes after stroke 16
 - in TIA 136
 - computed tomography (CT) in acute stroke 31–45
 - advantages 15, 16
 - compared with other imaging modalities 176
 - detection capability
 - arterial obstruction 32
 - brain tissue swelling 32
 - intracranial hemorrhage 31–2
 - ischemic brain edema 32–5
 - stroke location and extent 122, 125
 - diagnostic accuracy 35
 - arterial obstruction 36, 37
 - brain tissue swelling 36
 - intracranial hemorrhage 36
 - diagnostic impact 36–7
 - intracranial hemorrhage 37
 - ischemic brain edema 37–9, 40
 - impact on patient outcome 40–3
 - limitations 16–18
 - therapeutic impact 39–40
 - contrast-enhanced MRA (CE-MRA) 59
 - advantages 76, 88
 - compared with time of flight 89
 - contrast agent dosage and timing 88
 - drawbacks 88
 - technical considerations 88–9
 - contrast-enhanced T₁-weighted sequences 70–1, 73, 74, 76

264 Index

- creatine measurement by MRS 237, 241, 242
 CSI *see* chemical shift imaging (CSI)
 CT *see* computed tomography (CT)
 CTA *see* computed tomographic angiography (CTA)
 cytotoxic edema 69, 114
- dark blood techniques 85–6
 deoxyhemoglobin 105, 147–8
 diffusion tensor imaging (DTI) 59, 61
 diffusion–perfusion (DWI/PWI) mismatch 115, 180–1, 197, 200, 212
 diffusion-weighted MR imaging (DWI) 121–33
 clinical representations of results 121–2
 compared with other imaging modalities 176
 diagnosis of acute and chronic ischemia 177–9
 factors influencing lesion evolution 211–12
 false negatives 123
 infarct pathogenesis studies 182–3
 ischemic penumbra 196–9, 209–11
 motion artefacts 61
 multiple infarcts 126–7, 128, 129, 130
 in patient selection for therapy 183–5, 200, 224–5
 prognostic value 179–80
 and stroke extent 125–6
 and stroke location 122–4
 surrogate endpoint in drug trials 183, 214, 227–9
 technical aspects 59–61, 121
 therapeutic impact 127–8, 130, 131, 132
 thrombolytic therapy monitoring 212–13
 TIA studies 137–42
 typical examination 60–1
 in a typical stroke protocol 56
 see also animal stroke models: DWI studies
 digital subtraction angiography 6
 drug development *see* stroke drug development
- ECASS *see* European Cooperative Acute Stroke Studies (ECASS I and II)
 echoplanar magnetic resonance imaging (EPI) 21
 techniques summarized 177
 see also specific techniques
 elliptico-centric phase-encoding 89
 embolism, in stroke pathogenesis 7
 encephalitis, differentiation from infarct 81–3
 endothelin antagonist 118
 EPISTAR 63
 European Cooperative Acute Stroke Studies (ECASS I and II) 31, 36, 40–3, 208
 exametazime 22
 extracranial stenoses 89–91
- flow-driven adiabatic inversion 163–4
 fluid-attenuated inversion recovery (FLAIR) imaging 57–8, 70, 76, 77
 flumazenil 209
¹⁸F-fluoromisonidazole (FMISO) 193, 209
 FOCI pulses 167
 functional magnetic resonance imaging (fMRI) 251–61
- data analysis 253
 future directions 256–7
 mapping of normal functions 253
 paradigm selection 252
 stroke recovery studies 253–4, *cp*
 language recovery 255–6
 motor recovery 254–5
 other studies 256
 technical background 251–2
 trial design 252
- gadolinium
 magnetic susceptibility effect 149
 relaxivity effect 148, 149
 T1/T2 shortening 57, 58, 148
 use in MRA 59, 88
 use in PWI 62, 148–9
 gamma variate curves 62, 63
 glutamate/glutamine detection by MRS 243–4
 gradient echo sequences in PWI 149
 gyromagnetic ratio 234
- heat shock protein 70 (HSP 70) 194, 195
 hemodynamic stroke 7–8
 hemoglobin degradation 103
 hemorrhagic infarction 4, 77–9, 80–1
 Herpes simplex encephalitis 81–3
 hypertension 8
 hypoxia inducible factor 1 (HIF-1) 194, 195
- intracranial hemorrhage (ICH)
 blood pressure management 50–1
 detection by CT 31–2, 36, 37
 etiology 103, 104
 local pathological processes 109
 MRI
 hyperacute stage 104–8
 acute stage 103–4
 subacute and chronic stages 104
 etiological information 104
 signal characteristics summarized 104
 sensitivities of MRI and CT 103
 subarachnoid hemorrhage *see* subarachnoid hemorrhage (SAH)
 surgery for 108–9
 Xe CT 50–1
 intracranial stenoses 7, 93–4
 intracranial veins, imaging by MRA 97
 ischemic brain edema, detection by CT 32–5, 36, 37–9, 40
 ischemic core
 and DWI lesions 210, 211
 molecular definition 194
 operational definitions 197
 variability between patients 209
 ischemic penumbra 191–206
 biochemical definition 208
 current concept 212
 DWI of 196–9, 209–11
 DWI/PWI mismatch 115, 180–5, 197, 200, 212
 flow thresholds 192
 functional definition 191
 identification by PET 208–9
 importance 191
 molecular zones 194–5
- MRS of 185–6, 200–1, *cp*
 operational definitions 195, 197
 CT perfusion 196
 DWI/PWI 197
 PET 195–6
 SPECT 196
 Xe-CT 196
 PWI of 199, 211
 time-relatedness 192–3
 trials of prediction of response to therapy 184–5
- ischemic stroke diagnosis 9–10
 acute stroke 4–5
 approach summarized 6
 assessment of stroke risk factors 8
 importance in patient management 9–10
 stroke mechanism
 embolism 7
 hemodynamic stroke 7–8
 migrainous 8
 thrombosis 7
 stroke severity 9
 vascular lesions 5–6
- ischemic stroke management
 acute stroke 4, 5
 aortic lesions 6–7
 cardiac-origin embolism 6
 cervical vascular lesions 7
 hemodynamic stroke 8
 individualized 8, 9
 intracranial stenoses 7
 migrainous stroke 8
- k-space sampling 97–8
- lactate measurement by MRS 185, 186, 200–6, *cp*
 in cerebral ischemia 241–2
 levels and stroke outcome 245
 lacunar infarcts 3, 79, 182, 183
 language recovery poststroke, fMRI studies 255–6
 Larmor frequency 234
 lightbulb sign 178, 179
 lipid measurement by MRS 239, 241, 244
 longitudinal relaxation time (T₁) 55, 148
- magnetic resonance angiography (MRA)
 85–101
 clinical applications 76
 carotid and vertebral arteries 89–93, 94
 circle of Willis 93–7
 contrast-enhanced *see* contrast-enhanced MRA (CE-MRA)
 penumbral patterns 180–1
 phase-contrast 58–9, 75, 76, 78, 86–8
 principles 85
 time of flight 58, 59, 76, 85–6, 87, 89, 91
 in a typical stroke protocol 56
 work in progress 97–8
 magnetic resonance imaging (MRI)
 advantages in stroke 19
 appearances of ischemic infarction 70–6
 compared with other imaging modalities 176
 integrated stroke protocols 55, 56
 limitations in stroke 19–20

- practical application in acute stroke 5
 sensitivity to early ischemia 20
 T_1 -weighted *see* T_1 -weighted MRI
 T_2 -weighted *see* T_2 -weighted MRI
see also intracranial hemorrhage (ICH):
 MRI; *specific MRI modalities*
- magnetic resonance spectroscopy (MRS)
 233–50
 chemical shift imaging 185–6, 233, 234
 clinical utility 185–6, *cp*
 data collection 233
 equipment 234
 ischemic penumbra 185–6, 200–1, *cp*
 long and short echo time data 236, 238, 240
 normal spectrum 64, 65, 237
 N -acetyl aspartate 240–1
 choline 241
 creatine 241
 lipids/macromolecules 241
 nuclei applied 233
 outcome prediction 244–5, 247
 peaks in cerebral ischemia 241
 N -acetyl aspartate 242
 choline 242
 creatine 242
 glutamate/glutamine 243–4
 lactate 241–2
 lipids/macromolecules 239, 244
 principles 63–4, 234–6
 quantification of metabolites 236, 237, 238, 239
 reversible changes in metabolites 244
 selection of patients for treatment 247–8
 TIAs 137
 in understanding disability 245–6
 water suppression techniques 236
- magnetic resonance venography (MRV) 79, 80–1
- magnetization transfer 167
- magnetization transfer contrast (MTC) 76
- mean transit time (MTT) 61, 152, 154
- MELAS 244
- methemoglobin, shortening effects of 57, 58
- migrainous stroke 8
- motor recovery poststroke, FMRI studies 254–5
- moyamoya disease 95
- MRA *see* magnetic resonance angiography (MRA)
- MRI *see* magnetic resonance imaging (MRI)
- MRS *see* magnetic resonance spectroscopy (MRS)
- multiple sclerosis 244
- multivoxel MRS *see* chemical shift imaging (CSI)
- neural plasticity poststroke 254
- NeuroLite 22
- neuroprotective drugs, MRI studies in
 animals 116–17, 118, *cp*
- neurospectroscopy *see* magnetic resonance spectroscopy (MRS)
- NINDS trial 4, 36, 207
- oxyhemoglobin 105
- parallel imaging in MRA 98
- parenchymal hemorrhage detection
 CT 31–2
 MRI 78
- perfusion 61, 147
- perfusion-based fMRI 252
- perfusion-weighted MR imaging (PWI)
 147–59, *cp*
 clinical utility 155–6, 158, 179
 compared with other imaging modalities 176
 contrast agents
 endogenous 147–8, *see also* arterial spin labelling (ASL)
 exogenous 61–2, 148–9
 reasons for rapid bolus injection 152
 factors influencing lesion evolution 211–12
 image interpretation 154–6
 image postprocessing computations
 deconvolution 154
 mean transit time 152, 154
 rCBF 152–4
 rCBV 150–2
 infarct pathogenesis studies 182
 of ischemic penumbra 199, 211
 in patient selection for therapy 155, 183–5, 224
 prognostic value 179–80
 pulse sequences 149–50
 raw images 150, 151
 sample imaging parameters 150
 surrogate endpoint in drug trials 183, 214, 227–9
 thrombolytic therapy monitoring 212–13
 in a typical stroke protocol 56
see also animal stroke models: PWI studies;
 diffusion–perfusion (DWI/PWI)
 mismatch
- phase contrast MRA 58–9, 75, 76, 78, 86–8
- phosphocreatine (PCr) measurement by MRS 237, 241, 242
- positron emission tomography (PET)
 advantages in stroke 24
 compared with other imaging modalities 176
 image acquisition 23–4
 ischemic penumbra 192, 195–6, 197, 208–9
 language recovery studies 255
 limitations in stroke 24, 25
 measurements
 CBF 24
 CBV 24–5
 cerebral glucose metabolism 25
 cerebral oxygen metabolism 25
- pregnancy, CT in 16
- PROACT II trial 36, 113, 224
- proton density weighted images 58
- proton magnetic resonance spectroscopy *see* magnetic resonance spectroscopy (MRS)
- proUrokinase
 evaluation in rats 117–18
see also PROACT II trial
- pulsed magnetic field gradient technique 59–60
- PWI *see* perfusion-weighted MR imaging (PWI)
- randomized stroke trials, design problems 1–2
- reperfusion injury, DWI studies in animal models 114–15
- RS-87476 116
- rt-PA (tissue plasminogen activator) *see* thrombolytic therapy
- short tau inversion recovery (STIR) imaging 57–8
- single photon emission computed tomography (SPECT)
 advantages in stroke 21, 22–3, 177, *cps*
 compared with other imaging modalities 176
 image acquisition 21–2
 ischemic penumbra studies 192, 196, 197
 limitations 21, 23, 177, *cp*
 qualitative 22
 radiolabelled tracers 22
 semiquantitative 22
- spin echo sequences in PWI 149
- spin-lattice relaxation time (T1) 55, 148
- spiral imaging in MRA 97
- spreading depression 194, 195
- steady-state free precession (SSFP)
 techniques 97
- Stejskal–Tanner (ST) technique 59–60
- STIR (short tau inversion recovery) imaging 57–8
- stroke
 determination of prognosis 9
 diagnosis
 cerebral venous thrombosis 4
 hemorrhagic stroke 4
 importance in patient management 9–10
 initial step 3
 ischemic stroke *see* ischemic stroke
 diagnosis
 multiple possible causes 8–9
 new therapies 2
 pathology of ischemic infarction 69
 risk factors 8
 subtype classifications 2–3
 term 1
see also ischemic stroke management
- stroke drug development 223–31
 factors affecting clinical efficacy 225–6
 rational approach 17
- stroke trials
 design issues, MRI-based trials 230
 ongoing 230
 positive trials to date 113, *see also specific trials*
 traditional approach 223, 224
 use of animal models *see* animal stroke models
 use of MRI
 marker of therapeutic response 225–7
 outcome measure 225
 patient selection 224–5
 phase II trials 227
 surrogate marker in phase III trials 183, 214, 227–9
- stroke MRI protocols 55, 56
- Stroke Therapy Ancrod Trial (STAT) 113

266 Index

subarachnoid hemorrhage (SAH) CT 32, 108 MRI 20, 70, 108 Xe CT 51	thrombosis in stroke pathogenesis 7 TIAs <i>see</i> transient ischemic attacks (TIAs) time of flight (TOF) MRA 58, 59, 76, 85–6, 87, 89, 91 tissue plasminogen activator (rt-PA) <i>see</i> thrombolytic therapy TOAST stroke classification system 2, 3 TOF MRA <i>see</i> time of flight (TOF) MRA transcranial Doppler (TCD) 51, 93–4 transient ischemic attacks (TIAs) definitions conventional 135, 142 new (tissue-based) 143 research 143 time-based 142–3 diffusion MRI studies 137–42 clinical utility 141–2 pathophysiological insights 141 prognostic value 142 standard MRI studies 136 tissue patterns on MRI 135 transverse relaxation time (T_2) 58	vascular malformation, evaluation by MRA 96–7 vasogenic edema 69 vasospasm 51 velocity-encoding sensitivity (VENC) 86–7 venous infarcts 79 vertebral artery dissections 92, 93 Virchow–Robin spaces 79, 81 visual recovery poststroke, FMRI studies 256 voxels 253
surrogate endpoints 183, 214, 227–9		water suppression techniques (MRS) 236
T_1 -weighted MRI 55, 57–8, 70–6, 148 T_2 -shine-through effect 122 T_2 -weighted MRI 57, 58, 69–70, 70–5 <i>see also</i> fluid-attenuated inversion recovery (FLAIR) imaging T_2^* 4, 62, 235 ¹⁰⁵ technetium ethyl cysteinate dimer 22 ¹⁰⁵ technetium hexamethylpropyleneamine oxime (105Tc-HMPAO) 22	validation of MRI as a surrogate marker 228–9 variable projection method (VARPRO) 236, 238	X-ray angiography (XRA) 85, 89, 98 xenon enhanced CT (Xe CT) advantages 47–8 clinical applications 48 acute stroke 48–9, <i>cps</i> chronic cerebral ischemia 49–50 intracerebral hemorrhage 50–1 subarachnoid hemorrhage 51 vasospasm 51 ischemic penumbra studies 192, 196, 197 principle 47 technical problems 48
thrombolytic therapy clinical trials 4, 40–3, 184, 207–9, 224 future 214–9 monitoring by DWI/PWI 212–13 in animals 117–18 MRS studies of ischemic regions 248 patient selection by DWI/PWI 155–6, 183–5, 200, 224–5 limitations of CT 17–18 limitations of standard MRI 20 response related to baseline CT, ECASS findings 40–3		ZD9379 117